Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis

Gut. 2015 Apr;64(4):673-83. doi: 10.1136/gutjnl-2014-306748. Epub 2014 Jun 10.

Abstract

Objective: No therapy for non-alcoholic steatohepatitis (NASH) has been approved so far. Roux-en-y gastric bypass (RYGB) is emerging as a therapeutic option, although its effect on NASH and related hepatic molecular pathways is unclear from human studies. We studied the effect of RYGB on pre-existent NASH and hepatic mitochondrial dysfunction-a key player in NASH pathogenesis-in a novel diet-induced mouse model nicely mimicking human disease.

Design: C57BL/6J mice were fed a high-fat high-sucrose diet (HF-HSD).

Results: HF-HSD led to early obesity, insulin resistance and hypercholesterolaemia. HF-HSD consistently induced NASH (steatosis, hepatocyte ballooning and inflammation) with fibrosis already after 12-week feeding. NASH was accompanied by hepatic mitochondrial dysfunction, characterised by decreased mitochondrial respiratory chain (MRC) complex I and IV activity, ATP depletion, ultrastructural abnormalities, together with higher 4-hydroxynonenal (HNE) levels, increased uncoupling protein 2 (UCP2) and tumour necrosis factor-α (TNF-α) mRNA and free cholesterol accumulation. In our model of NASH and acquired mitochondrial dysfunction, RYGB induced sustained weight loss, improved insulin resistance and inhibited progression of NASH, with a marked reversal of fibrosis. In parallel, RYGB preserved hepatic MRC complex I activity, restored ATP levels, limited HNE production and decreased TNF-α mRNA.

Conclusions: Progression of NASH and NASH-related hepatic mitochondrial dysfunction can be prevented by RYGB. RYGB preserves respiratory chain complex activity, thereby restoring energy output, probably by limiting the amount of oxidative stress and TNF-α. These data suggest that modulation of hepatic mitochondrial function contributes to the favourable effect of RYBG on established NASH.

Keywords: FATTY LIVER; LIVER METABOLISM; NONALCOHOLIC STEATOHEPATITIS; OBESITY SURGERY; OXIDATIVE METABOLISM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Gastric Bypass*
  • Humans
  • Insulin Resistance
  • Liver Diseases
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria, Liver / physiology*
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Non-alcoholic Fatty Liver Disease / physiopathology
  • Non-alcoholic Fatty Liver Disease / surgery*
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor-alpha